

FACSIMILE TRANSMITTAL SHEET

ZymoGenetics, Inc.
1201 Eastlake Avenue East
Seattle, WA 98102 U.S.A.
Patent Department Facsimile Number: (206) 442-6678

PLEASE DELIVER TRANSMISSION TO: THIS TRANSMISSION IS FROM:

Name: Examiner Ruixiang Li

Name: Jennifer K. Johnson

Office: U.S. Patent Office

Date: March 15, 2004

Fax #: (571) 273-0875

Page 1 of 11

Operator: Kim Goplen

IF THERE ARE ANY PROBLEMS, PLEASE CALL (206) 442-6600

All information contained in this message is privileged, confidential and intended for the sole use of the individual(s) named above. If you are not the intended recipient, you are advised that any dissemination, distribution or copying of this communication is prohibited.

PATENT APPLICATION

File No: 00-22

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Cindy A. Sprecher, Julia E. Novak, James W. West, Scott R.
Presnell, Richard D. Holly, Andrew J. Nelson

Serial No. : 09/825,561

Group Art Unit : 1641

Examiner : Li, Ruixiang

Filed : April 3, 2001

For : SOLUBLE ZALPHA11 CYTOKINE RECEPTORS

Date Submitted : March 15, 2004

AMENDMENT FEE TRANSMITTAL

Mail Stop NON-FEE AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Transmitted herewith is an Amendment for the above-mentioned application.
The fee required to be filed with the accompanying amendment has been calculated as shown below:

CLAIMS AS AMENDED

	Claims Remaining After Amendment	Highest No. Covered by Previous Payments	Present Extra	Extra Rate	Fee
Total	28	- 47	0	\$9.00	\$000.00
Independent	4	- 13	0	\$43.00	\$000.00
1st Presentation of Multiple Dependent Claim				\$145.00	\$000.00
Total					\$000.00

Applicants claim small entity status. Please charge any required fee to
ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this sheet is enclosed.

Respectfully submitted,



Jennifer K. Johnson, J.D.
Registration No. 43,696

PATENT APPLICATION
File No: 00-22

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Cindy A. Sprecher, Julia E. Novak, James W. West, Scott R.
Presnell, Richard D. Holly, Andrew J. Nelson
Serial No. : 09/825,561
Group Art Unit : 1641
Examiner : Li, Ruixiang
Filed : April 3, 2001
For : SOLUBLE ZALPHA11 CYTOKINE RECEPTORS
Date Submitted : March 15, 2004

AMENDMENT FEE TRANSMITTAL

Mail Stop NON-FEE AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment for the above-mentioned application.
The fee required to be filed with the accompanying amendment has been calculated as shown below:

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest No. Covered by Previous Payments	Present Extra	Extra Rate	Fee
Total	28	- 47	0	\$9.00	\$000.00
Independent	4	- 13	0	\$43.00	\$000.00
1st Presentation of Multiple Dependent Claim				\$145.00	\$000.00
				Total	\$000.00

Applicants claim small entity status. Please charge any required fee to
ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this sheet is enclosed.

Respectfully submitted,


Jennifer K. Johnson, J.D.
Registration No. 43,696

PATENT APPLICATION

I hereby certify that this correspondence is being FAXed to Examiner Ruixiang Li at (571) 273-0875 at the US PTO and addressed to: Commissioner for Patents, Washington, D.C. 20231.

3-15-04
Date

Kim M. Goplen
Kim M. Goplen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Sprecher, Cindy A., Novak, Julia E., West, James W., Presnell,
Scott R., Holly, Richard D., and Nelson, Andrew J.
Application No. : 09/825,561
Filed : April 3, 2001
For : SOLUBLE ZALPHA11 CYTOKINE RECEPTORS

Examiner : Ruixiang Li
Art Unit : 1646
Docket No.: 00-22
Date : March 15, 2004

Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

SUPPLEMENTAL AMENDMENT

Dear Sir:

In consideration of allowable subject matter pursuant to the Office Action mailed November 12, 2003, Applicant is requesting that the following Supplemental Amendment be entered in addition to the Amendment mailed January 28, 2004, and the case allowed. Applicant respectfully requests consideration of the following amendments and remarks.